Therapeutic Reference Range for Olanzapine in Schizophrenia
Katja Wesner, Christoph Hiemke, Niels Bergemann, Karin Egberts, Stefanie Fekete, Manfred Gerlach, Ursula Havemann‐Reinecke, Xenija Lense, Thomas Riemer, Georgios Schoretsanitis, Manfred Uhr, Gerald Zernig, Gerhard Gründer, Xenia M. Hart
Abstract
-receptor occupancy for oral and long-acting injectable (LAI) formulations. . The process of study selection followed a previously published protocol and PRISMA guidelines. A total of 2,824 articles were identified through database search and 1 article via reference list check. Thirty-four studies were suitable for qualitative synthesis, and 13 studies were included in the quantitative analysis. Reviewers performed data extraction and quality assessment of the included studies independently following the review protocol. -receptor occupancy) between 17 and 44 ng/mL. We suggest a therapeutic reference range of 20-40 ng/mL for olanzapine oral and LAI formulations. In this range, optimal treatment response is expected in patients with schizophrenia and schizophrenia spectrum disorders. Side effects, especially weight gain, may already occur at therapeutic levels. However, higher plasma concentrations are in general well tolerated and should not necessarily require a dose reduction in case of good response and tolerance.